| Bioactivity | AST5902 mesylate is a principal metabolite of Alflutinib, exhibiting significant antineoplastic activity. AST5902 mesylate contributes to the overall pharmacological effects in the treatment of non-small cell lung cancer. AST5902 mesylate is involved in the response to activating EGFR mutations and can help overcome EGFR T790M drug-resistant mutations. |
| CAS | 2412155-75-8 |
| Formula | C28H33F3N8O5S |
| Molar Mass | 650.67 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers |
AST5902 mesylate
CAS: 2412155-75-8 F: C28H33F3N8O5S W: 650.67
AST5902 mesylate is a principal metabolite of Alflutinib, exhibiting significant antineoplastic activity. AST5902 mesyla
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.